Amgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
Recombinant Human Keratinocyte Growth Factor to Reduce Oral Mucositis in Hematologic Malignancy Patients Undergoing Peripheral Blood Stem Cell Transplantation After Radiation and High-dose Chemotherapy
Phase 3
Completed
- Conditions
- Stomatitis
- First Posted Date
- 2002-07-15
- Last Posted Date
- 2013-05-08
- Lead Sponsor
- Amgen
- Registration Number
- NCT00041665
A Rheumatoid Arthritis (RA) Study Treating Signs and Symptoms of RA in People With RA & Receiving Methotrexate
Phase 2
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2002-05-31
- Last Posted Date
- 2011-01-21
- Lead Sponsor
- Amgen
- Target Recruit Count
- 53
- Registration Number
- NCT00038298
Anemia in Patients With a Non-Myeloid Malignancy
- First Posted Date
- 2002-05-29
- Last Posted Date
- 2008-09-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 707
- Registration Number
- NCT00038064
Evaluation of the Efficacy of Combination Treatment With Anakinra and Pegsunercept in Improving Rheumatoid Arthritis
Phase 2
Completed
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2002-05-21
- Last Posted Date
- 2009-11-26
- Lead Sponsor
- Amgen
- Registration Number
- NCT00037700
Juvenile Rheumatoid Arthritis
- First Posted Date
- 2002-05-20
- Last Posted Date
- 2009-11-26
- Lead Sponsor
- Amgen
- Target Recruit Count
- 86
- Registration Number
- NCT00037648
A Study of an Investigational Medication for Severe Primary Hyperparathyroidism or Parathyroid Cancer
Phase 4
Completed
- Conditions
- HyperparathyroidismParathyroid Neoplasms
- First Posted Date
- 2002-05-20
- Last Posted Date
- 2013-05-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 46
- Registration Number
- NCT00037518
A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients
Phase 3
Completed
- Conditions
- Secondary HyperparathyroidismEnd Stage Renal Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2002-05-20
- Last Posted Date
- 2013-05-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 400
- Registration Number
- NCT00037635
Pegfilgrastim as Support to Pediatric Sarcoma Patients Receiving Chemotherapy
- First Posted Date
- 2002-05-06
- Last Posted Date
- 2010-02-26
- Lead Sponsor
- Amgen
- Target Recruit Count
- 44
- Registration Number
- NCT00035620
Chemotherapy Related Anemia
Phase 2
Completed
- Conditions
- AnemiaNon-Myeloid Malignancies
- Interventions
- First Posted Date
- 2002-05-06
- Last Posted Date
- 2013-05-13
- Lead Sponsor
- Amgen
- Target Recruit Count
- 120
- Registration Number
- NCT00035607
Pegfilgrastim as Support to Advanced Breast Cancer Patients Receiving Chemotherapy
- First Posted Date
- 2002-05-06
- Last Posted Date
- 2013-05-09
- Lead Sponsor
- Amgen
- Target Recruit Count
- 928
- Registration Number
- NCT00035594
© Copyright 2025. All Rights Reserved by MedPath